Sign In
Buy IGC
$0.300
+0.0100 (+3.45%)
At Close: Jun 03, 2026
Nokia deploys high-performance cross-border DWDM network for IGC
11:00pm, Sunday, 22'nd Sep 2024
Nokia's Dense Wavelength Division Multiplexing (DWDM) solution was used by IGC to overlay and enhance the existing infrastructure to more effectively manage the growing capacity demand.
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
08:00am, Wednesday, 18'th Sep 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment.
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
08:00am, Wednesday, 04'th Sep 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease.
IGC Pharma Reports First Quarter Fiscal 2025 Results
09:30pm, Thursday, 08'th Aug 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports First Quarter Fiscal 2025 Results.
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
09:10am, Tuesday, 09'th Jul 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile.
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
09:00am, Tuesday, 25'th Jun 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease.
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
07:30pm, Monday, 24'th Jun 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Reports Financial Results for Fiscal Year Ended March 31, 2024.
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
09:00am, Tuesday, 18'th Jun 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets.
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Publishes Study in European Society of Medicine.
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
09:00am, Tuesday, 28'th May 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1.
IGC Pharma to Attend BIO International Convention 2024
02:00pm, Tuesday, 21'st May 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Attend BIO International Convention 2024.
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
07:00am, Tuesday, 16'th Apr 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two.
IGC Pharma Adds Advisor in Artificial Intelligence
09:00am, Tuesday, 09'th Apr 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Adds Advisor in Artificial Intelligence.
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
03:00pm, Tuesday, 26'th Mar 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock.
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
11:00am, Wednesday, 20'th Mar 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation.
